BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Total External R&D Expense by Year
Total External R&D Expense ($M) ($M)
BeOne Medicines Total External R&D Expense: $859M in FY2025, up 17.8% from a year earlier.
Latest, FY2025
859
Period ended Dec 31, 2025
Change on a year earlier
+17.8%
729 in FY2024
History
6 years
Since FY2020
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Total external research and development expenses | 858,720 | 728,660 | 130,060 | 17.8 | %”
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K MD&A R&D Expense Summary Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total External R&D Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 859 | +17.8% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 729 | +11.8% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 652 | +2.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 637 | -5.9% | Form 10-K (filed 2023-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 677 | -7.2% | Form 10-K (filed 2022-02-28) ↗ |
| FY2020 | Dec 31, 2020 | 729 | – | Form 10-K (filed 2022-02-28) ↗ |
Breakdown
What makes up total External R&D Expense
Cite this data
StockData. (2026). BeOne Medicines Total External R&D Expense ($M), annual FY2020–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-external-tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.